Henry Kravis
Co-Founder and Co-Executive Chairman @ Kohlberg Kravis Roberts & Co.
New York, United States
Henry Kravis is a Series A investor at Kohlberg Kravis Roberts & Co. in New York focused on Software and Artificial Intelligence. Henry R. Kravis is the Co-Founder and Co-Executive Chairman of Kohlberg Kravis Roberts. He attended Claremont McKenna College.
- Total investments:
- 64
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Henry Kravis invests in
Stages Henry Kravis invests in
Countries Henry Kravis invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$24M
- Series A
- $9M–$43M
- Series B
- $17M–$140M
Investment Focus
Industry
- Software 15 (23%)
- Artificial Intelligence 9 (14%)
- SaaS 7 (11%)
- Financial Services 7 (11%)
- Information Technology 7 (11%)
Stage
- Series A 14 (22%)
- Seed 10 (16%)
- Series B 6 (9%)
- Series C 6 (9%)
- Private Equity 6 (9%)
Country
- United States 33 (52%)
- United Kingdom 3 (5%)
- India 2 (3%)
- United Arab Emirates 2 (3%)
- Japan 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Netomi is a provider of AI-first customer experience designed for the Relationship Economy. Netomi's AI-powered virtual agents automatically resolve 80% of routine customer service inquiries, decreasing resolution time, increasing customer satisfaction and support quality, while reducing costs. The patented, no-code platform works acrossmessaging, chat, email and voice, and understands 100+ languages. Netomi is based in San Mateo and has offices in New York, Toronto and India. | $110M / Series C / Apr 30, 2026 | ||
| Croissant is an application that resales products on behalf of customers. | $14M / Venture - Series Unknown / Feb 25, 2026 | ||
| Rogodevelops an artificial intelligence platform designed specifically for financial institutions such as investment banks, private equity firms, and asset managers. The platform integrates with internal systems and external financial data sources to analyze large volumes of information, including filings, market data, and proprietary datasets, anddeliver structured outputs like financial models, reports, and presentations. It uses AI models and agent-based systems to automate workflows such as research, due diligence, and market analysis, enabling users to complete multi-step financial tasks within a single system. The company’s technology is built with input from professionals with backgrounds in finance and is tailored to reflect the workflows and requirements of high-finance environments. Its tools are used by financial professionals to reduce manual work, support decision-making, and streamline processes across transactions and portfolio management. | $75M / Series C / Jan 28, 2026 | ||
| OpenEvidence provides an artificial intelligence medical information platform that organizes and synthesizes peer-reviewed clinical research to help physicians access evidence-based insights for clinical decision support. Its products include an AI-powered medical search engine that quickly retrieves and cites relevant literature from majorjournals and tools like DeepConsult that generate comprehensive research syntheses for complex clinical questions. The platform also integrates features that support clinical documentation and evidence retrieval during patient encounters, aiming to streamline how healthcare professionals find and apply clinical evidence. OpenEvidence delivers responses grounded in sourced medical research and supports workflows that assist clinicians in evaluating and interpreting medical knowledge. | $250M / Series D / Jan 21, 2026 | ||
| Semafor is the global news media. | $30M / Jan 07, 2026 | ||
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | ||
| Basic Capital offers a retirement benefit solution designed to enhance employee retention and wealth. It provides a platform that allows individuals to make significant long-term investments towards their retirement, with the flexibility to pay off over time. This innovative approach aims to revolutionize the retirement and wealth system in Americaby building a robust infrastructure. Basic Capital is venture capital-backed, indicating its growth potential and commitment to developing new financial solutions for retirement planning. With a focus on creating a more secure financial future for employees, Basic Capital stands out in the finance industry. | $25M / Series A / Aug 18, 2025 | ||
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $130M / Series C / Nov 21, 2024 | ||
| Kalshi is a federally regulated financial exchange that allows investors to trade directly on the anticipated outcome of future events. Kalshi’s markets cover a wide range of topics including economics, international affairs, media and entertainment, climate/weather, and public health. Because Kalshi’s market topics can be more specific thanother instruments like stocks or bonds, investors can get direct exposure to the events and trends that they are interested in. For example, a Kalshi market on whether a certain free trade agreement will be signed can help retail investors get exposure to emerging markets and fluctuations in international trade.Website: https://kalshi.com | $50M / Debt Financing / Oct 28, 2024 | ||
| Setpoint.io develops a platform purpose-built for modern real estate transactions. | $31M / Series B / Aug 13, 2024 | ||
| See all 64 investments → | |||
Co-Investors
Kohlberg Kravis Roberts & Co. provides investment and asset management services through private equity, credit, infrastructure, real estate, and capital markets businesses that deploy capital into companies and projects across multiple industries. The company manages investment funds and strategic accounts that pursue acquisitions, buyouts, growth equity, credit solutions, and real assets on behalf of institutional investors and partners. It engages in financial activities that include underwriting, financing arrangements, and tailored investment strategies designed to support business growth and long-term value creation. Kohlberg Kravis Roberts & Co. also collaborates with institutional clients to structure investment vehicles that align with specific capital objectives and portfolio goals.
Kohlberg Kravis Roberts & Co. Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ajay Candade
Director Private Equity
|
|||
Ali Satvat
Co-Head of Americas Private Equity Health Care
|
|||
Ashish Shastry
Co-Head of Private Equity for KKR Asia Pacific
|
|||
Blaine MacDougald
Director & Co-head of Credit Research, Credit
|
|||
Brandon Freiman
Partner, Head of North American Infrastructure
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Henry Kravis invest in?
Henry Kravis invests primarily in Software, Artificial Intelligence and SaaS startups, most often at Series A and Seed stage. Most of the 64 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Henry Kravis invest in?
Henry Kravis typically joins rounds of $1M–$24M at Seed, $9M–$43M at Series A and $17M–$140M at Series B. These are whole funding-round sizes, not Henry Kravis's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Henry Kravis took part in.
How do I contact Henry Kravis?
Public channels for Henry Kravis include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Henry Kravis last invest?
The most recent investment recorded for Henry Kravis closed in Apr 2026. Shizune tracks 64 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
